IP Library Granted Patent US 8,846,629
Granted Patent B2
US 8,846,629 · App. 12/326,832 · Granted Sep 30, 2014

Patent

Inventors: Pierre-Yves Desprez (Richmond, CA); Judith Campisi (Berkeley, CA)
Assignees: The Regents of the University of California; California Pacific Medical Center Research Institute
C12Q1/6876G01N33/57407G01N33/57415C12Q2600/158C12Q2300/156C12Q2600/106C12Q1/6886G01N33/57434G01N33/57492G01N33/5743
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,629
App. No.
12/326,832
Granted
Sep 30, 2014
Kind
B2
Abstract

A method for treatment and amelioration of breast, cervical, ovarian, endometrial, squamous cells, prostate cancer and melanoma in a patient comprising targeting Id-1 or Id-2 gene expression with a delivery vehicle comprising a product which modulates Id-1 or Id-2 expression.

Claims (13)

1. A method for treatment and amelioration of a cancer in prostate tissue and melanoma in a patient comprising:

a) providing a delivery vehicle comprising a product which inhibits Id-1 expression by disrupting Id-1 gene interaction—with a transcription factor, wherein said product is an RNAi; and

b) delivering said delivery vehicle to said patient.

2. The method of claim 1 wherein said cancer is melanoma.

3. The method of claim 1 wherein said cancer is prostate cancer.

4. The method of claim 1 wherein the cancer is melanoma.

5. The method of claim 1 , wherein the delivery vehicle further comprises a vector containing the molecule, wherein the vector is selected from the group consisting of an adenoviral vector, adeno-associated viral vector, lenti viral or retroviral vector, cationic liposome vector, and a polycationic polymer or a polyplex vector.

6. The method of claim 1 wherein said delivering step is carried out intravenously, orally or by injection.

7. A method for treatment and amelioration of a breast cancer in a patient comprising the steps of:

a) providing a delivery vehicle comprising a molecule that disrupts Id-1 gene interaction with a transcription factor, wherein said molecule is an RNAi that reduces Id-1 gene expression levels resulting in reduction of Id-1 protein levels, wherein said reduction in Id-1 protein levels disrupts Id-1 gene interaction with a transcription factor, and

b) delivering said delivery vehicle to said patient.

8. The method of claim 7 , wherein the delivery vehicle further comprises a vector containing the molecule, wherein the vector is selected from the group consisting of an adenoviral vector, adeno-associated viral vector, lentis viral or retroviral vector vector, a cationic liposome vector, and a polycationic polymer or a polyplex vector.

9. The method of claim 7 wherein said delivering step is carried out intravenously, orally or by injection.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 4, 2010
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: ENERGY, UNITED STATE DEPARTMENT OF
Reel/Frame 024787/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2008
From: DESPREZ, PIERRE-YVES
To: CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE
Reel/Frame 021920/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2008
From: CAMPISI, JUDITH
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 021920/0742 →
Continuity (5)
Division 11390682 · Mar 27, 2006
Continuation 09952534 · Sep 14, 2001
Provisional Application 60232529 · Sep 14, 2000
Provisional Application 60232558 · Sep 14, 2000
Related Publication 20090180988A1 · Jul 16, 2009